Not available
Quote | Merck & Company Inc. (NYSE:MRK)
Last: | $129.12 |
---|---|
Change Percent: | 1.67% |
Open: | $129.69 |
Close: | $127 |
High: | $132.8 |
Low: | $128.76 |
Volume: | 4,918,724 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Merck & Company Inc. (NYSE:MRK)
2024-04-25 07:56:55 ET More on Bristol-Myers Squibb Company Is Bristol Myers Squibb A Buy At These Bottom Levels? Bristol-Myers Squibb: Market Pessimism Won't Last Forever Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade) Bristol-...
2024-04-25 07:10:53 ET More on Merck Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck: Better Times Ahead On Approvals And Outlook Merck Non-GAAP EPS of $2....
Message Board Posts | Merck & Company Inc. (NYSE:MRK)
Subject | By | Source | When |
---|---|---|---|
$MRK reports 1Q23 resultsraises non-GAAP EPS guidance: | DewDiligence | investorshub | 04/27/2023 1:08:25 PM |
$MRK acquires RXDX for $10.8B | DewDiligence | investorshub | 04/17/2023 4:37:16 PM |
A Delaware judge ruled today that $MRK remains | DewDiligence | investorshub | 04/03/2023 10:07:28 PM |
Keytruda shows statsig-superior PFS as addend to chemo | DewDiligence | investorshub | 03/27/2023 9:52:42 PM |
whytestocks: $MRK News Article - KEYTRUDA (pembrolizumab) Plus Chemotherapy Significantly Improved O | whytestocks | investorshangout | 03/10/2023 3:25:48 PM |
News, Short Squeeze, Breakout and More Instantly...
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NA...
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
Sales Reflect Continued Strong Growth in Oncology and Vaccines Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 12% KEYTRUDA Sales Grew 20% to $6.9 Billion; Excluding the Impact of Foreign Exchange, S...